Komori
General Meetings of Shareholders4588Oncolys BioPharma Inc.Pharmaceuticals

Notice Regarding the Results of the Ordinary General Meeting of Shareholders and Other Matters

At the ordinary general meeting of shareholders held on 24 March 2026, all 3 proposals were approved: the election of 5 directors, partial amendments to the Articles of Incorporation, and the reduction of stated capital and capital reserve and appropriation of surplus. Following the meeting, the Board of Directors also decided the directors’ positions and a 5-member executive officer structure.

Worth reading
81Important
Scored from 2 of 4 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Resolutions for the General Meeting of Shareholders

Annual General Meeting of Shareholders
2026
Mar 24
Date and time(start time: Not disclosed)
Matters for resolution3 items
  1. Election of 5 directors

  2. Partial Amendments to the Articles of Incorporation

  3. Reduction of stated capital and capital reserve and appropriation of surplus

Director nominee
5Nominees
1New
2Outside
Resolutions for the General Meeting of Shareholders
ItemDetails
Type of shareholders' meetingAnnual General Meeting of Shareholders
Date and time24 March 2026 (start time: Not disclosed)
Matters for resolutionProposal 1: Election of 5 directors, Proposal No. 2: Partial Amendments to the Articles of Incorporation, Proposal 3: Reduction of stated capital and capital reserve and appropriation of surplus
Director nominee5 director candidates, including 1 new candidate and 2 outside directors
Items this document does not state (2)
Shareholder ProposalPercentage voting in favor

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The company is announcing that resolutions were passed at the ordinary general meeting of shareholders held on 24 March 2026, and that the positions of directors and executive officers were decided at the Board of Directors meeting held after the general meeting. No specific reasons for the individual proposals or the appointment of executive officers are stated.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Results of the Ordinary General Meeting of Shareholders and Other Matters | Oncolys BioPharma Inc. (4588) timely disclosure | Komori